Pharvaris NV Insider Trades: CEO Buys at €2.59 While Selling Near €30, Signaling Strong Long‑Term Confidence in Rare‑Disease Pipeline.

Insider Activity Snapshot On April 29, 2026, Chief Medical Officer Lu Peng executed a Rule 10b‑5‑1 scheduled purchase of 3,733 shares at €2.59 each, increasing his stake to 69,816 shares. This purchase is part of a broader 10b‑5‑1 exercise that also included the sale of 3,733 shares at €30.06 the same day and a subsequent sale of 15,000 shares at €30.24 on April 30. The dual buy‑sell pattern is typical of a pre‑planned trading plan designed to mitigate market timing concerns.

What the Moves Mean for Investors The €2.59 purchase price is far below the current market price of €25.40, suggesting that Lu is buying at a substantial discount—an indicator that insiders see long‑term upside. In contrast, the high‑price sales reflect the vesting of restricted units and a routine exercise of the 10b‑5‑1 plan. Overall, the net effect is a modest increase in insider holdings, reinforcing confidence in the company’s pipeline. For investors, this activity signals that management’s valuation of Pharvaris remains positive despite the recent 92.73 % yearly jump and the high‑profile upcoming trials for oral B2 receptor antagonists.

Lu Peng’s Trading Profile Across the past few weeks, Lu has alternated between buying at low prices (often the €2.59 level) and selling at the market peak (~€30). His recent history includes selling 7,001 shares at €30.05 on April 22, buying 7,001 shares at €2.59 on April 22, and selling 100 shares at €30.03 on April 23. This pattern reflects a disciplined 10b‑5‑1 strategy rather than opportunistic trading. Lu’s consistent use of the plan, combined with a steady increase in holdings, underscores a long‑term commitment to Pharvaris’s therapeutic agenda.

Company‑Wide Insider Context Other insiders, such as Chief Early Development Officer Anne Lesage, have been active, alternating between low‑price purchases (≈€2.59) and high‑price sales (≈€30). CEO Berndt Modig’s recent sales at ~€28–€29 indicate a broader trend of insiders managing liquidity while maintaining significant positions. The volume of trades is modest relative to the company’s €1.64 billion market cap, suggesting that insider activity is routine and unlikely to destabilize the stock.

Bottom Line for Analysts The latest transactions reaffirm that key executives view Pharvaris’s rare‑disease pipeline favorably. The buy‑sell rhythm aligns with regulatory best practices, and the net insider holdings are trending upward. For investors, the lesson is clear: despite short‑term price swings, the insider confidence remains robust, and the company’s upcoming clinical milestones are likely to continue driving value.